XML 21 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6
Liquidity and Capital Resources (Details) (USD $)
9 Months Ended
Sep. 30, 2012
Dec. 31, 2011
Sep. 30, 2011
Dec. 31, 2010
Estimated projected expenditure [Line Items]        
Cash and cash equivalents $ 12,453,637 $ 17,988,590 $ 30,387,583 $ 6,324,430
Marketable securities 10,000,000 18,057,672    
Net proceeds from the issuance of common shares 0 18,900,000 18,943,119  
Currently projected expenditures for clinical programs 20,000,000      
Subsequent Event [Member]
       
Estimated projected expenditure [Line Items]        
Net proceeds from the issuance of common shares 21,400,000      
Aldoxorubicin [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 7,800,000      
Bafetinib [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 200,000      
Tamibarotene [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 3,000,000      
General Operation [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs 2,100,000      
Other General and Administrative Expenses [Member]
       
Estimated projected expenditure [Line Items]        
Currently projected expenditures for clinical programs $ 6,900,000